PBM Psyence Biomedical Ltd.
Listings ·
Shareholders gave Psyence's board authority to consolidate the common shares at a ratio of up to 250:1, but the board has not set a ratio or timing, and the company says a consolidation may never happen.
The deal covers 1,000,000 common shares at $2.00 each, plus two series of warrants. H.C. Wainwright & Co. is placement agent.
Psyence Biomedical Ltd. is a clinical-stage biopharmaceutical company that works with natural psilocybin for palliative care treatment. Its product used in the Phase IIb study is NPX-5, described as capsules containing 25mg of naturally sourced psilocybin. The field of use is anxiety and depression, including associated ailments such as PTSD, stress, grief and adjustment disorder within the context of palliative care. The company's principal capital expenditures in progress consist of funding that Phase IIb trial in Australia, conducted through Southern Star Research Pty Ltd and its subsidiary Psyence Australia. It replaced PEX010, a botanical drug candidate licensed from Filament Health Corp., with NPX-5 from PsyLabs as the candidate in the Phase IIb study. The company has also invested in PsyLabs, which the text describes as a privately held company headquartered in the British Virgin Islands that focuses on psychedelic active pharmaceutical ingredients and extracts, and which it describes as part of a multi-asset, vertically integrated platform for psychedelic-based therapeutics. The company's common shares and public warrants trade on Nasdaq under PBM and PBMWW, following a business combination with Newcourt Acquisition Corp. that concluded on January 25, 2024.
| Product or program | What it is | Stage |
|---|---|---|
| NPX-5 | Capsules containing 25mg naturally sourced psilocybin for anxiety and depression | Phase IIb |
| Line | FY ended Mar 31, 2025 | FY ended Mar 31, 2024 |
|---|---|---|
| Research and development | $342,168 | $954,593 |
| Net income (loss) | $1.0 million | -$51.2 million |
| Cash from operations | -$3.7 million | -$2.9 million |
| Cash and equivalents | $6.1 million | $733,188 |
Our latest story on this, dated Dec 31, 2024: "Psyence Biomedical agrees to $2.0 million private placement with warrants". The story links the filing or release it is based on. Read the story.
Psyence Biomedical Ltd. trades under the ticker PBM on NASDAQ.
Psyence Biomedical Ltd. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Psyence Biomedical Ltd. is 1985062. Its filings are on SEC EDGAR.
2,293,277 shares as of 2026-03-31, per the cover page of its 20-F filed 2026-06-22.
Our directory records Psyence Biomedical Ltd. under Canada.
Our directory classifies Psyence Biomedical Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Psyence Biomedical Ltd. is CA74449F4078.
aibio.space lists Psyence Biomedical Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A6.
Psyence Biomedical Ltd. is a clinical-stage biopharmaceutical company that works with natural psilocybin for palliative care treatment. Its product used in the Phase IIb study is NPX-5, described as capsules containing 25mg of naturally sourced psilocybin.
NPX-5: Capsules containing 25mg naturally sourced psilocybin for anxiety and depression Stage: Phase IIb.
Psyence Biomedical Ltd. reported net income of $1.0 million for the fiscal year ended Mar 31, 2025, and used $3.7 million of cash in operations, per its annual report to the SEC.
$342,168 in the fiscal year ended Mar 31, 2025, per its annual report.
$7.1 million in cash at Sep 30, 2025, per its 6-K.
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio